Literature DB >> 14520180

Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel.

Zmira Samra1, Edna Scherf, Michael Dan.   

Abstract

BACKGROUND AND GOAL: The changing epidemiology of genital herpes with the increasing importance of herpes simplex virus (HSV) type 1 prompted a study on the relative prevalence of HSV-1 and HSV-2 among cases of genital herpes in the Tel Aviv area, Israel. STUDY
DESIGN: A retrospective laboratory-based study of positive genital and nongenital herpes cultures performed at the Beilinson Medical Center between 1993 and 2002. Data regarding the number of isolates of each type and the age and sex of patients with genital lesions were retrieved from the database. Cultures were performed using Vero cells, and positive results were confirmed and typed by immunofluorescence.
RESULTS: A total of 285 positive genital cultures and 659 positive nongenital cultures were recorded. HSV-1 was identified in 189 (66.3%) of the positive genital specimens and in 656 (99.55%) of the nongenital specimens. HSV-1 was isolated in 174 of 262 (66.4%) female subjects and 15 of 23 (65.2%) male subjects. The proportion of HSV-1 genital isolates was 72.7% in patients 15 to 24 years of age, 62% in those 25 to 44 years, and 46% in those aged 45 years or older. Overall, the annual isolation rate of genital HSV-1 has not changed markedly over the years.
CONCLUSION: Herpes simplex virus type 1 has clearly been the predominant HSV type isolated from genital specimens in the Tel Aviv area over the last decade.

Entities:  

Mesh:

Year:  2003        PMID: 14520180     DOI: 10.1097/01.OLQ.0000079517.04451.79

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  25 in total

1.  Should sexually transmitted disease clinics routinely offer serologic testing for genital herpes?

Authors:  Michael F Rein
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.725

Review 2.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

3.  Toxoplasma gondii seropositivity and co-infection with TORCH pathogens in high-risk patients from Qatar.

Authors:  Marawan A Abu-Madi; Jerzy M Behnke; Haydee A Dabritz
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

5.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

6.  Herpes simplex virus type 1 is the leading cause of genital herpes in New Brunswick.

Authors:  Richard Garceau; Danielle Leblanc; Louise Thibault; Gabriel Girouard; Manon Mallet
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

7.  2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.

Authors:  Mårten Strand; Koushikul Islam; Karin Edlund; Christopher T Oberg; Annika Allard; Tomas Bergström; Ya-Fang Mei; Mikael Elofsson; Göran Wadell
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 8.  [Herpes simplex virus infections].

Authors:  G Gross
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

Review 9.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Psychological stress exacerbates primary vaginal herpes simplex virus type 1 (HSV-1) infection by impairing both innate and adaptive immune responses.

Authors:  Kathleen A Ashcraft; Robert H Bonneau
Journal:  Brain Behav Immun       Date:  2008-06-27       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.